| Literature DB >> 30073092 |
Carlos Fernández Moro1,2, Béla Bozóky2, Marco Gerling3,4.
Abstract
BACKGROUND: Colorectal cancer liver metastases (CRLM) grow in distinct histological patterns that have been associated with outcome after surgical resection. We conducted a systematic review to evaluate the frequency of different CRLM growth patterns and their impact on prognosis.Entities:
Keywords: colorectal cancer; colorectal metastases; hepatic metastases; histopathology
Year: 2018 PMID: 30073092 PMCID: PMC6067357 DOI: 10.1136/bmjgast-2018-000217
Source DB: PubMed Journal: BMJ Open Gastroenterol ISSN: 2054-4774
Figure 1Study flow diagram according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. One study15was included specifically for outcome data, as it reported the outcome for a cohort published in a more recent article13; this study was excluded due to overlapping cohort from the main series. Another study27 included two independent patient cohorts that were reported separately; this study is counted as one item.
Overview of eligible studies included
| Study | Title | Publication year | Time period | Location | Male | Female | Primary in colon | Primary in rectum | Synchronous | Metachronous | Desmoplastic CRLM (%) | Pushing CRLM (%) | Replacement | Mixed | Capsule independent | Outcome assessed | Preoperative chemo |
| van Dam |
| 2017 | 2000–2015 | Department of Surgical Oncology, Erasmus MC Cancer Institute (Rotterdam, The Netherlands) | 241 | 133 | 204 | 170 | 243 (defined as <1 year) | 131 | 49 | 3 | 47 | 1, excluded from survival analysis; >50% predominance | N | Y | ≥44% of patients |
| Frentzas |
| 2016 | 2006–2012 | The Royal Marsden Hospital (RM), London, UK | 21 | 12 | 12 | 21 | NA | NA | 52.5 | 1.7 | 45.8 | NA | N | Y | All bev+chemo |
| Frentzas |
| 2016 | 2008–2014 | McGill University Health Centre (MUHC), Montréal, Canada | 35 | 24 | 39 | 20 | NA | NA | 51.6 | 3.1 | 45.3 | NA | N | Y | All bev+chemo |
| Siriwardana |
| 2016 | 1998–2008 | Royal Free Hospital, | 18 | 8 | 18 | 6 | 7 | 19 | 43.3 | NA | 43.3 | 10 | N | Y | N |
| Serrablo |
| 2016 | 2004–2010 | NA, Spain and/or Italy | NA | NA | NA | NA | NA | NA | 17 | 52.3 | 46.3 | NA | Y | Y | Reported separately |
| Eefsen |
| 2015 | 2007–2011 | Rigshospitalet, Copenhagen, Denmark | 146 | 91 | 162 | 75 | 146 | 91 | 29.5 | 37.1 | 14.8 | 18.6 | N | N (for same cohort in ref | Reported separately |
| Brunner |
| 2014 | 2004–2010 | Regensburg, Germany | 118 | 83 | 119 | 82 | NA | NA | 37.8 | NA | NA | NA | N | Y | Reported separately |
| Pinheiro |
| 2014 | 2000–2009 | NA, likely Sao Paulo, Brazil | 50 | 41 | NA | NA | 43 | 48 | NA | 40.7 | 59.3 | NA | N | Y | Reported separately |
| Wiggans |
| 2012 | 2010–2011 | Derriford Hospital, UK | 40 | 26 | NA | NA | 38 | 28 | 41.5 | NA | NA | NA | N | Y | Mixed |
| Nyström |
| 2012 | 1998–2009 | Västerbotten County, | 25 | 23 | 29 | 18 | NA | NA | 45.8 | 52.1 | NA | NA | N | Y | Mixed |
| Van Den Eynden |
| 2012 | 1997–2005 | Royal Hallamshire Hospital, Sheffield, UK | NA | NA | 104 | 91 | 101 | 98 | 34.6 | 15.6 | 27.8 | 17.6 | N | Y | NA |
| Rajaganeshan |
| 2007 | 1993–2004 | St James’s University | 60 | 49 | NA | NA | 19 | 90 | 34.8 | NA | NA | NA | N | Y | Untreated group reported in ref |
| Stessels |
| 2004 | NA | General Hospital Sint-Augustinus and of the University Hospital of | NA | NA | NA | NA | NA | NA | 50 | 17.9 | 32.1 | NA | N | N | NA |
| Terayama |
| 2002 | NA | Kanazawa University School of Medicine, Japan | 24 | 5 | NA | NA | NA | NA | 10.5 | NA | NA | NA | N | N | NA |
| Yamaguchi |
| 2002 | 1981–1998 | Nagasaki University | NA | NA | NA | NA | NA | NA | NA | 38.1 | 61.9 | NA | N | Y | NA |
| Vermeulen |
| 2001 | NA | University Hospital Antwerp and AZ Sint-Augustinus, Belgium | NA | NA | NA | NA | NA | NA | 42.3 | 46.2 | 11.5 | NA | N | N | Excluded |
| Weber |
| 2001 | 1988–1998 | Hôpital Universitaire de Hautepierre, Strasbourg, France | 132 | 89 | 142 | 76 | 90 | 131 | 28.5 | 34.8 | 65.2 | NA | Y | Y | NA |
| Lunevicius |
| 2001 | 1983–1997 | Aichi Cancer Center, | NA | NA | NA | NA | NA | NA | 20.3 | NA | NA | NA | N | Y | NA |
| Okano |
| 2000 | 1992–1996 | National Cancer Center Hospital, Tokyo, Japan | 104 | 48 | NA | NA | 46 | 106 | 61.1 | NA | NA | NA | N | Y | NA |
| Ambiru |
| 1999 | 1984–1997 | Chiba University School of Medicine, Japan | 104 | 62 | 109 | 53 | 71 | 91 | 27.9 | NA | NA | NA | N | Y | NA |
| Nagashima |
| 1999 | 1981–1994 | Tokyo University Hospital, Japan | 48 | 11 | NA | NA | 24 | 35 | 80 | 91.5 | 8.5 | NA | Y | Y | NA |
| Terayama |
| 1996 | NA | Kanazawa University | 6 | 7 | 13 | NA | NA | NA | 15.4 | 76.9 | 7.7 | NA | N | N | NA |
| Yamamoto |
| 1995 | 1991–1992 | National Cancer Center Hospital, Tokyo, Japan | 26 | 14 | 27, multiple primaries | 12, multiple primaries | 8 | 32 | 70 | NA | NA | NA | N | N | NA |
| Morino |
| 1991 | 1980–1986 | Kyoto University Hospital, Japan | 16 | 13 | 12 | 17 | 11 | 18 | 27.6 | 20.7 | 34.5 | 41.4 | Y | Y | NA |
Clinicopathological data were extracted as specified in the Methods section.
bev, bevacizumab; chemo, conventional cytotoxic chemotherapy; CRLM, colorectal cancer liver metastases; N, no; NA, not available; Y, yes.
Figure 2Word cluster diagram of colorectal cancer liver metastases growth pattern terminology. Original terms for the histological growth patterns in the literature are shown in a font size proportional to their absolute frequency (n=22 studies, not considering the consensus guidelines18 as these already reflect a distillate from previous studies). These are grouped and coloured by similarity into ‘consensus terms’ (‘desmoplastic’, green; ‘pushing’, blue; and ‘replacement’, red). The filled green shape indicates terms related to ‘capsule’.
Figure 3Classification systems and reported frequencies of colorectal cancer liver metastases (CRLM) growth patterns. (A) Overall reported frequencies of CRLM growth patterns. Heterogeneous expressions used to describe growth patterns between studies were grouped by similarity with respect to their individual terms and associated descriptions into ‘consensus terms’ (related to figure 2). (B) Number of growth patterns considered in each study. Note that some studies regarded the presence/absence of a fibrotic capsule as a parameter independent of the histological growth patterns—that is, ‘desmoplastic’ metastases could be simultaneously classified as ‘pushing’ or ‘replacement’. ‘Mixed’ patterns are not included, as they do not define a specific category. (C) Percentage frequencies of reported growth patterns by study, according to consensus terms. For studies (in italics) in which a capsule was assessed independently, its frequency is represented in a separate bar. Note: In some studies, single metastases could not be classified by the reporting authors, in which case the bars do not add up to 100%. Although Terayama et al 42 considered a total of four growth patterns the description of ‘sinusoidal’ was considered to closely represent the ‘replacement’ pattern in this specific study and counted as such. GP, growth pattern.
Figure 4Reported frequencies stratified according to preoperative chemotherapy. (A) Percentage frequencies of reported growth patterns by study, grouped according to treatment: no preoperative treatment, cytotoxic chemotherapy, or cytotoxic chemotherapy plus bevacizumab. For studies (in italics) in which the capsule was assessed independently, its frequency is represented in a separate bar. Studies that reported both treated and untreated patients are grouped and indicated with grey or white background. The total number of patients in each study cohort is given to the right of each bar. (B) Reported frequencies for the three treatment groups; lines indicate minimum and maximum, filled circle indicates median (frequency in %). Note: The mixed pattern was reported in one study only for chemo and bev-chemo groups. bev, bevacizumab; chemo, conventional cytotoxic chemotherapy.
Figure 5Impact of main growth patterns on prognosis. First column: The desmoplastic pattern is characterised by a rim of fibrotic stroma (green) that separates tumour cells from the surrounding hepatocytes. Second column: In the replacement pattern, tumour cells (grey) invade along the liver cell plates, replacing the hepatocytes (yellow). Third column: In the pushing pattern, the liver plates adjacent to the metastases appear flattened (arrowheads); blue: central veins. (A) Dot plot of all studies reporting outcome for every growth pattern; one dot corresponds to one study; (B) as in (A), but only considering studies published prior to Food and Drug Administration’s (FDA) approval of bevacizumab (indicated by thick line in online supplementary table 2). Note that some studies found effects for more than one pattern.